Biotech Values

[DewDiligence]

NAMS goes public via SPAC merger with FLAC:

https://www.globenewswire.com/news-release/2022/11/23/2561557/0/en/NewAmsterdam-Pharma-Debuts-as-Publicly-Traded-Company-Focused-on-Developing-Obicetrapib-a-Low-Dose-Once-Daily-Oral-LDL-Lowering-Agent-with-Promising-Safety-and-Efficacy-Clinical-Da.html

NewAmsterdam (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated.

NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients.

…In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease.